Source comparison
Tesamorelin + Ipamorelin Blend: Protocol Comparison
Weeks 1–4 (Titration) 1mg Tesamorelin + 200mcg Ipamorelin daily Fasted state, within 30min of waking, 90min pre-meal Minimal (tolerance phase) Injection site tolerance, transient water retention Establishes baseline tolerance. Visceral fat reduction not expect
This comparison does not assign a generated winner or score.
- Weeks 1–4 (Titration)
- 1mg Tesamorelin + 200mcg Ipamorelin daily
- Fasted state, within 30min of waking, 90min pre-meal
- Minimal (tolerance phase)
- Injection site tolerance, transient water retention
- Establishes baseline tolerance. Visceral fat reduction not expected during this phase
- Weeks 5–12 (Active Reduction)
- 2mg Tesamorelin + 300mcg Ipamorelin daily
- Same fasted-state protocol
- 8–15% VAT volume reduction
- Waist circumference (−2 to −5cm), fasting glucose improvement
- Primary treatment window. Most measurable visceral adipose loss occurs here
- Weeks 13–26 (Maintenance)
- 2mg Tesamorelin + 300mcg Ipamorelin 5 days/week
- Sustained reduction, minimal further loss
- Stable waist circumference, metabolic markers
- Prevents VAT rebound. Full daily dosing can be reduced to 5x/week without reversal
- Post-Protocol (Discontinuation)
- None
- N/A
- VAT regain of 40–60% within 12 weeks if discontinued
- Gradual waist circumference increase
- Peptide-driven VAT reduction reverses without continued GH stimulus. This is a biological reality, not protocol failure